Gaucher Disease
📧 Sign up to get email alerts when something new happens for Gaucher Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2023-08-09Clinical Trial Update: An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 [Phase 2, Phase 3]
A clinical trial evaluating AVR-RD-02 for Gaucher disease type 3 was withdrawn after being studied in Phase 2/3.
-
EMA withdrawal · 2012-11-23EMA Refused: Elelyso (taliglucerase alfa) — Pfizer Ltd.
The EMA refused the marketing authorization for Elelyso (taliglucerase alfa) by Pfizer Ltd., in the Gaucher disease indication.